Aptose Biosciences (TSE:APS) Upgraded by Alliance Global Partners to Strong-Buy Rating

Alliance Global Partners upgraded shares of Aptose Biosciences (TSE:APS) (NASDAQ:APTO) to a strong-buy rating in a research note published on Thursday,Zacks.com reports.

Aptose Biosciences Trading Down 7.2 %

TSE APS opened at C$4.36 on Thursday. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The stock’s 50-day simple moving average is C$8.67 and its two-hundred day simple moving average is C$12.27. Aptose Biosciences has a twelve month low of C$0.16 and a twelve month high of C$5.29. The company has a market capitalization of C$187.73 million, a price-to-earnings ratio of -0.87 and a beta of 1.36.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.